abs267.txt	background		women	with	hiv	face	an	increased	risk	of	human	papillomavirus	(hpv)acquisition	and	persistence		cervical	intraepithelial	neoplasia		and	invasivecervical	cancer		our	objective	was	to	determine	the	cost-effectiveness	ofdifferent	cervical	cancer	screening	strategies	among	women	with	hiv	in	southafrica	methods		we	modified	a	mathematical	model	of	hpv	infection	and	cervical	diseaseto	reflect	coinfection	with	hiv		the	model	was	calibrated	to	epidemiologic	datafrom	hiv-infected	women	in	south	africa		clinical	and	economic	data	were	drawnfrom	in-country	data	sources		the	model	was	used	to	project	reductions	in	thelifetime	risk	of	cervical	cancer	and	incremental	cost-effectiveness	ratios(icers)	of	pap	and	hpv	dna	screening	and	management	algorithms	beginning	at	hivdiagnosis		at	1-		2-		or	3-year	intervals		strategies	with	an	icer	below	southafrica's	2016	per	capita	gross	domestic	product	(us$5270)	were	considered	cost-effective		results		hpv	testing	followed	by	treatment	(test-and-treat)	at	2-year	intervalswas	the	most	effective	strategy	that	was	also	cost-effective		reducing	lifetimecancer	risk	by	56	6%	with	an	icer	of	us$3010	per	year	of	life	saved		othercost-effective	strategies	included	pap	(referral	threshold		hsil+)	at	1-		2-		and3-year	intervals		and	hpv	test-and-treat	at	3-year	intervals		pap	(ascus+)		hpvtesting	with	16/18	genotyping		and	hpv	testing	with	pap	or	visual	triage	ofhpv-positive	women	were	less	effective	and	more	costly	than	alternatives	conclusions		considering	per	capita	gross	domestic	product	as	the	benchmark	forcost-effectiveness		hpv	test-and-treat	is	optimal	in	south	africa		at	lowercost-effectiveness	benchmarks		pap	(hsil+)	would	be	optimal	
